BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from ...

Calls have emerged for a comprehensive redesign of the drug development system as delays in global Phase 2 and 3 clinical ...

Lumen Bioscience has announced positive results from the RePreve Clinical Trial of oral LMN-201, an investigational biologic cocktail drug, that demonstrate a statistically significant global cure and ...

MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...

Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately $2.5 million ...

HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory HQ-CT scores fell by Week 2 ...

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume. Aardvark will host a webcast to ...

The Ibogaine Club Research Group, an independent research resource focused on ibogaine safety data and treatment center protocols, has submitted a formal public comment to the U.S. Food and Drug ...

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ...

Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded ...

The Negative Lists raise the thresholds that trigger data export mechanisms, easing compliance burdens and exempting certain transfers from the ...